

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

EVELYNE LOPEZ, ET AL.

Application No.:

Filed:

For: METHOD FOR PREPARING A COMPOSITION BY
MOTHER-OF-PEARL EXTRACTION, COMPRISING
INTEGRALLY MOTHER-OF-PEARL COMPONENTS,
COMPOSITION OBTAINED BY SAID METHOD AND USE
THEREOF IN COSMETICS AND DERMATOLOGY

Art Group:

Examiner:

Assistant Commissioner for Patents
Washington, D.C. 20231

TRANSMITTAL OF FORMAL DRAWINGS


Sir:

Enclosed herewith for filing in the above-identified U.S. Patent Application are the formal drawings.
15 sheets including 20 Figures. Applicant hereby authorizes any additional extension or petition fees under 37
C.F.R. §1.17 or credit for any overpayment to our Deposit Account No. 02-2666. A copy of the Fee
Transmittal sheet is enclosed.

Respectfully submitted.

BLAKELY, SOKOLOFF, TAYLOR & ZAFMAN

Dated: 4/13/02


Eric S. Hyman, Reg. No. 30,139

12400 Wilshire Blvd., 7th Floor
Los Angeles, California 90025
Telephone: (310) 207-3800




Figure 1 : Western blot of composition A

▪ The 110 kDa and 140 kDa marks are calculated from the equation $rf = f(\log MW)$

10/089982





Figure 2: Western blot (continued) of composition A

* The 110 kDa and 140 kDa marks are calculated from the equation $rf=f(\log MW)$.

1: Biochemical detection of alkaline phosphatase activity
2: Immunochemical detection of the presence of alkaline phosphatase

5



20

Figure 3 : Overall amino acid composition of the protein phase of composition A

25





Figure 4: cytokeratin synthesis by human keratinocytes (control culture)




Figure 5: effect of composition A on cytokeratin synthesis by human keratinocytes



Figure 6: human keratinocytes in culture subjected to estradiol withdrawal
(control culture)




Figure 7: effect of composition A on human keratinocytes in culture subjected to
estradiol withdrawal




Figure 8: cyokeratin synthesis by human keratinocytes in culture subjected to estradiol withdrawal (control culture)



Figure 9: effect of composition A prepared according to the invention on cytikeratin synthesis by human keratinocytes in culture subjected to estradiol withdrawal




Figure 10: elastin synthesis by human fibroblasts (control culture)



Figure 11: effect of composition A on elastin synthesis by human fibroblasts



Figure 12: effect of estrogens on fibroblasts from an explant from a menopausal women undergoing replacement therapy (control culture for figure 14)



Figure 13: effect of estrogens on fibroblasts from an explant from a menopausal women undergoing replacement therapy: culture in the presence of estradiol and then withdrawal and observation 1 hour after rinsing (control culture for figure 15)




Figure 16: effect of composition A on melanocytes: modification of the amount of melanin taken up by keratinocytes cultured in the presence of composition A




Figure 14: effect of composition A on fibroblasts subjected to estradiol withdrawal, from an explant from a menopausal women undergoing replacement therapy (see control culture in figure 12)



Figure 15: effect of composition A on fibroblasts, subjected to estradiol withdrawal, from an explant from a menopausal woman undergoing replacement therapy: culture in the presence of estradiol, then estradiol withdrawal and addition of composition A. Observation 1 hour after rinsing (see control culture in figure 13)



Figure 17: coculture of human keratinocytes and melanocytes. Amount of melanin taken up by the cultured human keratinocytes (control)



Figure 18: effect of composition A on the amount of melanin taken up by cultured human keratinocytes




Figure 19: effect of composition A on interleukin (IL-1) secretion by HL60 promyelocytic cells




Figure 20: study of the noncytotoxicity of the composition prepared according to the invention: optical density measurements